A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
The Thai Lymphoma Study Group
UNICANCER
Wake Forest University Health Sciences
Stanford University
University of Nebraska
University of Nebraska
University of Nebraska
Thomas Jefferson University
Chonnam National University Hospital
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Northwestern University
Masonic Cancer Center, University of Minnesota
Mayo Clinic
Case Comprehensive Cancer Center
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Mayo Clinic
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Mayo Clinic
Roswell Park Cancer Institute
Mayo Clinic
Roswell Park Cancer Institute
Mayo Clinic
University of Chicago
Swiss Cancer Institute
Case Comprehensive Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
Virginia Commonwealth University
Ohio State University Comprehensive Cancer Center
Ruijin Hospital
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Wake Forest University Health Sciences
University of Washington
Fred Hutchinson Cancer Center
University of Washington
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center